PCK2

Across TCGA pan-cancer cohorts, PCK2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PCK2 data layer compared with 23 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher PCK2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PCK2 expression acts as an unfavorable survival marker.

THYM, LUSC, and STAD are the cancer types where PCK2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	All	0.604	0.967	<.001	27	view →
LUSC	OS	Median	All	0.162	0.678	<.001	27	view →
STAD	OS	Median	All	0.226	0.734	.003	15	view →
LIHC	OS	Median	II,III,IV	0.198	0.715	.012	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PCK2–THYM (OS)

Open the THYM breakdown →